National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
January 24, 2012 • Volume 9 / Number 2


Genetic Abnormality Predicts Treatment Benefit for Patients with Rare Brain Tumor

Cells from an oligodendgroglioma tumor The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor. Patients in the study had anaplastic oligodendrogliomas, but only those whose tumors contained a genetic abnormality known as the 1p19q co-deletion experienced a benefit from adding chemotherapy to radiation. 

The finding, from a phase III trial in which patients were followed for a median of 11 years, will lead to changes in an ongoing NCI-sponsored clinical trial as well as in the standard of care for patients who are not enrolled in a clinical trial. NCI and the Radiation Therapy Oncology Group (RTOG) announced the finding January19 in coordinated press releases. Read more > >


Attendees at Women Science Advisors luncheon

A Conversation with the NCI Women Scientist Advisors

Drs. Katherine McGlynn and Mary Ward discuss recent activities and future plans of the NCI Women Scientist Advisors, a group created to represent the career interests of women scientists at NCI and NIH.



  • FDA Update

    • Glucarpidase Approved to Lower Toxic Chemotherapy Levels in the Blood
    • New Warnings Added for Lymphoma Drug
  • Notes

    • NIH and Industry Create "Living Lab" to Study Molecular Structures and Disease
    • CURE Report Focuses on Reducing Disparities in the Cancer Workforce

Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information about cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at

Next Section >